IDSA 2026 Gram-Negative Empiric Therapy Recommendations
The IDSA 2026 guidance prioritizes risk-stratified empiric therapy for antimicrobial-resistant Gram-negative infections, with treatment selection based on local resistance patterns, prior colonization data, and individual patient risk factors for ESBL-producing Enterobacterales, carbapenem-resistant organisms, and difficult-to-treat resistant Pseudomonas aeruginosa 1.
Key Principles from IDSA 2026
The 2026 IDSA guidance represents a paradigm shift toward individualized risk assessment rather than one-size-fits-all empiric regimens 1. The document specifically addresses:
- ESBL-producing Enterobacterales (ESBL-E)
- AmpC β-lactamase-producing Enterobacterales (AmpC-E)
- Carbapenem-resistant Enterobacterales (CRE)
- Difficult-to-treat resistant Pseudomonas aeruginosa (DTR-PA)
- Carbapenem-resistant Acinetobacter baumannii (CRAB)
- Stenotrophomonas maltophilia
Risk-Adapted Empiric Therapy Algorithm
Step 1: Assess Patient Risk Factors
High-risk patients requiring broad-spectrum coverage include those with:
- Prior intravenous antibiotic use within 90 days 2
- Known colonization with resistant organisms 1, 3
- Healthcare-associated infection 4
- Septic shock or severe physiologic disturbance 4
- Immunocompromised state (transplant, malignancy, intensive chemotherapy) 3
- Prolonged hospitalization (≥5 days) 4
Step 2: Review Local Resistance Data
Critical decision point: Quinolones should NOT be used empirically unless local E. coli susceptibility exceeds 90% 4. This threshold reflects the widespread fluoroquinolone resistance that has emerged globally.
Step 3: Select Empiric Regimen Based on Infection Severity and Risk
For Community-Acquired Infections (Low-Moderate Severity)
First-line options:
- Amoxicillin-clavulanate 5
- Ceftriaxone or cefotaxime + metronidazole (for intra-abdominal sources) 5
- Ampicillin + gentamicin + metronidazole 5
Avoid: Ampicillin-sulbactam due to high E. coli resistance rates 4
For High-Severity or Healthcare-Associated Infections
Preferred broad-spectrum regimens:
- Piperacillin-tazobactam 4, 5
- Meropenem, imipenem-cilastatin, or doripenem (carbapenems) 4
- Cefepime or ceftazidime + metronidazole (for intra-abdominal sources) 4
For suspected ESBL-E: Carbapenems remain the gold standard, though newer β-lactam/β-lactamase inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam) are now first-line options when metallo-β-lactamases are ruled out 6.
For Suspected Carbapenem-Resistant Organisms
When CRE is suspected based on risk factors:
- Ceftazidime-avibactam (first choice for non-metallo-β-lactamase CRE) 6
- Meropenem-vaborbactam 6
- Imipenem-relebactam 6
- Cefiderocol (reserve for metallo-β-lactamase producers or when other options fail) 6
For Difficult-to-Treat Resistant Pseudomonas
Preferred empiric coverage when DTR-PA suspected:
- Ceftolozan-tazobactam (preferred first choice) 6
- Ceftazidime-avibactam 6
- Imipenem-relebactam 6
- Cefiderocol (reserve for metallo-β-lactamase-producing strains) 6
Double antipseudomonal coverage is recommended ONLY for patients with: risk factors for MDR organisms, prior antibiotic exposure within 90 days, septic shock, or known colonization 2. Combine a β-lactam (from column B) with either a fluoroquinolone or aminoglycoside (from column C) 2.
Critical Pitfalls to Avoid
1. Overuse of Broad-Spectrum Agents
Using carbapenems or novel β-lactam combinations for low-risk community infections increases resistance pressure and toxicity risk without improving outcomes 4. Reserve these agents for documented resistant organisms or high-risk patients.
2. Empiric Enterococcal Coverage
Do NOT provide empiric enterococcal coverage for community-acquired infections 4. Enterococcal coverage IS indicated for:
- Healthcare-associated infections 4
- Postoperative infections 4
- Patients with prior cephalosporin exposure 4
- Immunocompromised patients 4
- Valvular heart disease or prosthetic vascular materials 4
3. Aminoglycoside Monotherapy
Aminoglycosides should NOT be used as monotherapy for empiric Gram-negative coverage in adults 4. They may be added as part of combination therapy for high-risk patients or severe infections, but meta-analyses show lower clinical response rates compared to β-lactam-based regimens 2.
4. Ignoring Rapid Diagnostics
While rapid diagnostic testing provides genotypic resistance data that can be challenging to interpret (especially for non-fermenter bacteria), it significantly reduces time to appropriate therapy 3. Incorporate rapid diagnostics into your empiric decision-making when available.
De-escalation Strategy
Once culture and susceptibility data are available:
- Narrow spectrum to the most targeted agent 4
- Discontinue unnecessary Gram-positive coverage (e.g., vancomycin) 4
- Discontinue antifungal therapy if yeast not isolated 4
- Consider transition to oral therapy when clinically improving, able to take oral medications, and effective oral option available 7
For complicated UTIs with Gram-negative bacteremia: Transition to oral antibiotics provides similar efficacy to continued parenteral therapy when the oral agent is active against the pathogen and achieves therapeutic levels 7.
Duration Considerations
The 2026 guidance emphasizes shorter treatment courses when appropriate 1. For intra-abdominal infections following adequate source control, 10 days of therapy post-surgical debridement is sufficient for moderate-to-severe infections 8.
Geographic and Institutional Variability
This guidance is US-focused 1. Local antibiograms must drive empiric choices, as resistance patterns vary dramatically by region and institution 4, 9. Update institutional protocols based on your facility's resistance data, ideally quarterly or when significant epidemiologic shifts occur 2.